Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants |
| |
| Authors: | Maxime P. Vallée Tonya L. Di Sera David A. Nix Andrew M. Paquette Michael T. Parsons Russel Bell Andrea Hoffman Frans B. L. Hogervorst David E. Goldgar Amanda B. Spurdle Sean V. Tavtigian |
| |
| Affiliation: | 1. Department of Molecular Medicine, CHUQ Research Center, Quebec City, Canada;2. Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, Utah;3. ARUP Laboratories, University of Utah School of Medicine, Salt Lake City, Utah;4. Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah;5. QIMR Berghofer Medical Research Institute, Brisbane, Australia;6. Netherlands Cancer Institute, Amsterdam, The Netherlands;7. Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah |
| |
| Abstract: | Clinical mutation screening of the cancer susceptibility genes BRCA1 and BRCA2 generates many unclassified variants (UVs). Most of these UVs are either rare missense substitutions or nucleotide substitutions near the splice junctions of the protein coding exons. Previously, we developed a quantitative method for evaluation of BRCA gene UVs—the “integrated evaluation”—that combines a sequence analysis‐based prior probability of pathogenicity with patient and/or tumor observational data to arrive at a posterior probability of pathogenicity. One limitation of the sequence analysis‐based prior has been that it evaluates UVs from the perspective of missense substitution severity but not probability to disrupt normal mRNA splicing. Here, we calibrated output from the splice‐site fitness program MaxEntScan to generate spliceogenicity‐based prior probabilities of pathogenicity for BRCA gene variants; these range from 0.97 for variants with high probability to damage a donor or acceptor to 0.02 for exonic variants that do not impact a splice junction and are unlikely to create a de novo donor. We created a database http://priors.hci.utah.edu/PRIORS/ that provides the combined missense substitution severity and spliceogenicity‐based probability of pathogenicity for BRCA gene single‐nucleotide substitutions. We also updated the BRCA gene Ex‐UV LOVD, available at http://hci‐exlovd.hci.utah.edu, with 77 re‐evaluable variants. |
| |
| Keywords: | BRCA1 BRCA2 cancer predisposition unclassified variant variant of uncertain significance rare variant |
|
|
